Key Highlights:
- Indian Immunologicals Limited, in collaboration with the Indian Council of Medical Research, has moved an indigenous vaccine candidate for Kyasanur Forest Disease (also known as monkey fever) into Phase I human trials in India.
- The investigational vaccine is a two-dose, adjuvanted inactivated formulation developed following a request from the Government of Karnataka. Preclinical and toxicity studies have been completed, and GLP-grade vaccine material has been produced to support the transition to clinical testing.
- If the early trial demonstrates safety and an adequate immune response, the vaccine will move to larger clinical studies before seeking approval from the Central Drugs Standard Control Organisation, potentially strengthening prevention efforts against the disease in the Western Ghats region
Implications:
IIL grabs first-mover advantage in niche viral vaccine space, dominating government tenders and regional immunization drives.
Homegrown breakthrough smashes import dependence, positioning IIL as next infectious disease champion beyond COVID/rabies success.
Source: INDIAMEDTODAY
